Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1993 1
1994 3
1995 2
1996 1
1997 3
1999 1
2009 2
2010 1
2013 3
2014 3
2015 4
2016 1
2017 1
2018 2
2019 3
2020 2
2021 3
2022 4
2023 2
2024 3
2025 4
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety.
Palmer CL, Boras B, Pascual B, Li N, Li D, Garza S, Huser N, Yuan JT, Cianfrogna JA, Sung T, McMillan E, Wei N, Carmody J, Kang AN, Darensburg S, Dodd T, Oakley JV, Solowiej J, Nguyen L, Orr STM, Chen P, Johnson E, Yu X, Diehl WC, Gallego GM, Jalaie M, Ferre RA, Cho-Schultz S, Shen H, Deal JG, Zhang Q, Baffi TR, Xu M, Roh W, Lapira-Miller J, Goudeau J, Yu Y, Gupta R, Kim K, Dann SG, Kan Z, Kath JC, Nair SK, Miller N, Murray BW, Nager AR, Quinlan C, Petroski MD, Zhang C, Sacaan A, VanArsdale T, Anders L. Palmer CL, et al. Among authors: vanarsdale t. Cancer Cell. 2025 Mar 10;43(3):464-481.e14. doi: 10.1016/j.ccell.2025.02.006. Cancer Cell. 2025. PMID: 40068598 Free article.
Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity.
Arora M, Moser J, Hoffman TE, Watts LP, Min M, Musteanu M, Rong Y, Ill CR, Nangia V, Schneider J, Sanclemente M, Lapek J, Nguyen L, Niessen S, Dann S, VanArsdale T, Barbacid M, Miller N, Spencer SL. Arora M, et al. Among authors: vanarsdale t. Cell. 2023 Jun 8;186(12):2628-2643.e21. doi: 10.1016/j.cell.2023.05.013. Epub 2023 Jun 1. Cell. 2023. PMID: 37267950 Free article.
Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor.
Freeman-Cook K, Hoffman RL, Miller N, Almaden J, Chionis J, Zhang Q, Eisele K, Liu C, Zhang C, Huser N, Nguyen L, Costa-Jones C, Niessen S, Carelli J, Lapek J, Weinrich SL, Wei P, McMillan E, Wilson E, Wang TS, McTigue M, Ferre RA, He YA, Ninkovic S, Behenna D, Tran KT, Sutton S, Nagata A, Ornelas MA, Kephart SE, Zehnder LR, Murray B, Xu M, Solowiej JE, Visswanathan R, Boras B, Looper D, Lee N, Bienkowska JR, Zhu Z, Kan Z, Ding Y, Mu XJ, Oderup C, Salek-Ardakani S, White MA, VanArsdale T, Dann SG. Freeman-Cook K, et al. Among authors: vanarsdale t. Cancer Cell. 2021 Oct 11;39(10):1404-1421.e11. doi: 10.1016/j.ccell.2021.08.009. Epub 2021 Sep 13. Cancer Cell. 2021. PMID: 34520734 Free article.
Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance.
Chen P, Lee NV, Hu W, Xu M, Ferre RA, Lam H, Bergqvist S, Solowiej J, Diehl W, He YA, Yu X, Nagata A, VanArsdale T, Murray BW. Chen P, et al. Among authors: vanarsdale t. Mol Cancer Ther. 2016 Oct;15(10):2273-2281. doi: 10.1158/1535-7163.MCT-16-0300. Epub 2016 Aug 5. Mol Cancer Ther. 2016. PMID: 27496135
A lymphotoxin-beta-specific receptor.
Crowe PD, VanArsdale TL, Walter BN, Ware CF, Hession C, Ehrenfels B, Browning JL, Din WS, Goodwin RG, Smith CA. Crowe PD, et al. Among authors: vanarsdale tl. Science. 1994 Apr 29;264(5159):707-10. doi: 10.1126/science.8171323. Science. 1994. PMID: 8171323
An allosteric cyclin E-CDK2 site mapped by paralog hopping with covalent probes.
Zhang Y, Liu Z, Hirschi M, Brodsky O, Johnson E, Won SJ, Nagata A, Bezwada D, Petroski MD, Majmudar JD, Niessen S, VanArsdale T, Gilbert AM, Hayward MM, Stewart AE, Nager AR, Melillo B, Cravatt BF. Zhang Y, et al. Among authors: vanarsdale t. Nat Chem Biol. 2025 Mar;21(3):420-431. doi: 10.1038/s41589-024-01738-7. Epub 2024 Sep 18. Nat Chem Biol. 2025. PMID: 39294320 Free PMC article.
The ligands and receptors of the lymphotoxin system.
Ware CF, VanArsdale TL, Crowe PD, Browning JL. Ware CF, et al. Among authors: vanarsdale tl. Curr Top Microbiol Immunol. 1995;198:175-218. doi: 10.1007/978-3-642-79414-8_11. Curr Top Microbiol Immunol. 1995. PMID: 7774281 Review. No abstract available.
18F-FLT PET, a Noninvasive Pharmacodynamic Biomarker of Tumor Cell Proliferation, Detected Differential Response to Various Cyclin-Dependent Kinase (CDK) Inhibitors.
Giddabasappa A, Jiang ZK, Yang B, Chen L, Liu F, Cabral E, Ram S, Boras B, Huser N, Zhang CC, Noorbehesht K, Manzuk LK, Visswanathan R, Mojtahedzadeh S, Affolter T, Carmody J, Kang AN, Petroski MD, Khamphavong PL, VanArsdale T, Nguyen QD, Maresca KP, Dann SG. Giddabasappa A, et al. Among authors: vanarsdale t. Mol Cancer Ther. 2025 Jul 2;24(7):1111-1122. doi: 10.1158/1535-7163.MCT-24-0856. Mol Cancer Ther. 2025. PMID: 40116733 Free PMC article.
46 results